Sign up to save your podcasts
Or
Share Ep. 162 - New CMS Payment Models, China Markets Outlook, & Zhang's Latest Start-Up
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ep. 162 - New CMS Payment Models, China Markets Outlook, & Zhang's Latest Start-Up
On the latest BioCentury This Week podcast, BioCentury’s editors discuss what the latest payment models from CMS could mean for cell and gene therapies, and how a new model could incentivize the completion of confirmatory trials for drugs with accelerated approval. BioCentury's editors also discuss the outlook for China's public markets and details around the genetic medicine delivery technology of recently launched Aera Therapeutics.
Reach us by sending a text
View all episodes
By BioCentury
4.8
3232 ratings
On the latest BioCentury This Week podcast, BioCentury’s editors discuss what the latest payment models from CMS could mean for cell and gene therapies, and how a new model could incentivize the completion of confirmatory trials for drugs with accelerated approval. BioCentury's editors also discuss the outlook for China's public markets and details around the genetic medicine delivery technology of recently launched Aera Therapeutics.
Reach us by sending a text
More shows like BioCentury This Week
View all
Freakonomics Radio
32,271 Listeners
Bloomberg Intelligence
413 Listeners
Odd Lots
1,986 Listeners
Nature Podcast
760 Listeners
The Long Run with Luke Timmerman
126 Listeners
The Readout Loud
338 Listeners
Making Sense
70 Listeners
Thoughts on the Market
1,316 Listeners
Biotech 2050 Podcast
62 Listeners
Business Of Biotech
87 Listeners
MIT Technology Review Narrated
264 Listeners
Biotech Hangout
21 Listeners
WSJ's Take On the Week
149 Listeners
The Top Line
15 Listeners
The BioCentury Show
12 Listeners